Form 4: KalVista Pharmaceuticals Acquired by Chiesi Farmaceutici

Director Laurence Reid reports the cancellation of stock options following the completion of KalVista Pharmaceuticals' acquisition by Chiesi Farmaceutici.

Summary

• KalVista Pharmaceuticals, Inc. has been acquired by Chiesi Farmaceutici S.p.A. via a cash tender offer.
• The acquisition price was set at $27.00 per share.
• The merger was finalized on June 11, 2026, with KalVista becoming a wholly owned subsidiary of Chiesi.
• Reporting person Laurence Reid held 17,000 stock options with an exercise price of $10.07, which were cancelled and converted into a cash payment per the merger agreement.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event as it represents the final administrative step of a previously announced acquisition.

Positives

• Shareholders received a cash consideration of $27.00 per share.
• Outstanding stock options with an exercise price below the merger consideration were converted into cash payouts.

Negatives

• Company ceases to be an independent publicly traded entity.
• Stock options with an exercise price equal to or greater than the merger consideration were cancelled for no consideration.

Risks

• The company is no longer a standalone public entity, eliminating future upside potential for public shareholders.

Future Outlook

The company has been acquired and is now a wholly owned subsidiary of Chiesi Farmaceutici; no further public guidance is provided.

Management Comments

• The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026.

Industry Context

StockSavvy.ai notes that this acquisition reflects the ongoing trend of large pharmaceutical companies acquiring specialized biotech firms to bolster their pipelines, particularly in rare disease or specialized therapeutic areas.

Comparison to Industry Standards

• The $27.00 per share cash offer represents a standard exit strategy for mid-cap biotech firms in the current M&A environment.
• The treatment of unvested options is consistent with standard change-in-control provisions in executive compensation agreements.

Stakeholder Impact

• Shareholders receive cash for their holdings.
• Employees and management transition to a subsidiary structure under Chiesi Farmaceutici.

Next Steps

• Delisting of KalVista Pharmaceuticals common stock from public exchanges.

Key Dates

Keywords

KalVista Pharmaceuticals, Chiesi Farmaceutici, Merger, Acquisition, Form 4, Tender Offer, Biotech